Tae Hyung Han - Concepedia

Author

Tae Hyung Han

Seagen (United States)

Also Known As

S.I. Kim, T H Han, T Han, T. H. Han, T. Han, T.-H. Han, T.H. Han, Tae H HAN, Tae H Han, Tae H. Han

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Seagen (United States)Merck & Co., Inc., Rahway, NJ, USA (United States)University of Alabama at Birmingham City Of Hope National Medical Center The University of Texas MD Anderson Cancer Center

About

Tae Hyung Han is an author at Seagen (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	826
2	Emergency Medicine	2	2	72
3	Health Sciences	1	1	13
4	Social Sciences	1	1	36
5	Anesthesia	1	1	59

Tae Hyung Han

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, The Lancet Oncology Dll3-targeted Antibody-drug ConjugateMedicineImmunologyImmune Checkpoint InhibitorCancer Treatment	2016	537
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies Michelle A. Fanale, Andres Forero‐Torres, Joseph D. Rosenblatt, Clinical Cancer Research	2011	213
Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects Kenneth C. Lasseter, Jay J. Gambale, Bo Jin, The Journal of Clinical Pharmacology Drug SafetyOral Nk1 AntagonistOncologyHealthy SubjectsPreclinical Drug Evaluation	2007	132
CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies Tae Hyung Han, Ajay K. Gopal, Radhakrishnan Ramchandren, The Journal of Clinical Pharmacology	2013	99
Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy Rajesh Krishna, Barry Gumbiner, C. Melinda Stevens, Clinical Pharmacology & Therapeutics	2009	83
Bispectral Index Does Not Correlate with Observer Assessment of Alertness and Sedation Scores During 0.5% Bupivacaine Epidural Anesthesia with Nitrous Oxide Sedation Kyong Soo Park, Eun Jin Hur, Kyung Woo Han, Anesthesia & Analgesia Observer AssessmentPerioperative MedicineBispectral Index DoesSurgeryPain Management	2006	59
Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment Baiteng Zhao, Robert Chen, Owen A. O’Connor, British Journal of Clinical Pharmacology	2016	59
Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies Hong Li, Tae Hyung Han, Naomi Hunder, The Journal of Clinical Pharmacology	2017	55
Evaluation of the safety, pharmacokinetics and treatment effects of an α<sub>ν</sub>β<sub>3</sub> integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases Mark Rosenthal, Peter J. Davidson, Frédéric Rolland, Asia-Pacific Journal of Clinical Oncology	2010	51
Fluoxetine inhibits A-type potassium currents in primary cultured rat hippocampal neurons Jin‐Sung Choi, Bok Hee Choi, Hye Sook Ahn, Brain Research Hyperpolarization (Biology)NeurophysiologyMedicineSynaptic TransmissionPhysiology	2004	36

Page 1